[go: up one dir, main page]

NO994929D0 - Syntetiske peptider, nyttige i biologiske tester, for paavisning av infeksjoner foraarsaket av gruppe 0 HIV-1 virus - Google Patents

Syntetiske peptider, nyttige i biologiske tester, for paavisning av infeksjoner foraarsaket av gruppe 0 HIV-1 virus

Info

Publication number
NO994929D0
NO994929D0 NO994929A NO994929A NO994929D0 NO 994929 D0 NO994929 D0 NO 994929D0 NO 994929 A NO994929 A NO 994929A NO 994929 A NO994929 A NO 994929A NO 994929 D0 NO994929 D0 NO 994929D0
Authority
NO
Norway
Prior art keywords
radical
seq
peptide sequence
formula
val
Prior art date
Application number
NO994929A
Other languages
English (en)
Other versions
NO994929L (no
NO329149B1 (no
Inventor
Denis Marie Bernard Chenebaux
Jean-Francois Hubert Delagneau
Stephane Jean Xavier Gadelle
Francois Yves Unier
Original Assignee
Pasteur Sanofi Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26233456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994929(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9704356A external-priority patent/FR2761993B1/fr
Priority claimed from FR9802212A external-priority patent/FR2775287B1/fr
Application filed by Pasteur Sanofi Diagnostics filed Critical Pasteur Sanofi Diagnostics
Publication of NO994929D0 publication Critical patent/NO994929D0/no
Publication of NO994929L publication Critical patent/NO994929L/no
Publication of NO329149B1 publication Critical patent/NO329149B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19994929A 1997-04-09 1999-10-08 Syntetiske peptider, blandinger, immunoassaymetode og diagnostiseringssett NO329149B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9704356A FR2761993B1 (fr) 1997-04-09 1997-04-09 Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih 1 groupe 0
FR9802212A FR2775287B1 (fr) 1998-02-24 1998-02-24 Peptides synthetiques consensus utilisables dans les essais biologiques pour la detection des infections dues aux virus vih 1 du groupe o
PCT/FR1998/000691 WO1998045323A1 (fr) 1997-04-09 1998-04-06 Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih-1 du groupe o

Publications (3)

Publication Number Publication Date
NO994929D0 true NO994929D0 (no) 1999-10-08
NO994929L NO994929L (no) 1999-12-08
NO329149B1 NO329149B1 (no) 2010-08-30

Family

ID=26233456

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994929A NO329149B1 (no) 1997-04-09 1999-10-08 Syntetiske peptider, blandinger, immunoassaymetode og diagnostiseringssett

Country Status (20)

Country Link
US (2) US7053175B1 (no)
EP (1) EP0973802B1 (no)
JP (1) JP3560987B2 (no)
KR (1) KR100451312B1 (no)
CN (1) CN1215082C (no)
AT (1) ATE343590T1 (no)
AU (1) AU740231B2 (no)
BR (1) BRPI9809078B8 (no)
CA (1) CA2286344C (no)
CZ (1) CZ300927B6 (no)
DE (1) DE69836265T2 (no)
ES (1) ES2275305T3 (no)
IL (2) IL132166A0 (no)
NO (1) NO329149B1 (no)
NZ (1) NZ500015A (no)
PL (1) PL194863B1 (no)
PT (1) PT973802E (no)
RU (1) RU2184742C2 (no)
TR (1) TR199902757T2 (no)
WO (1) WO1998045323A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE343590T1 (de) * 1997-04-09 2006-11-15 Bio Rad Pasteur Synthetische peptide für testverfahren zur bestimmung der infektion mit virus hiv1 der gruppe o
CA2676762C (en) * 1998-11-30 2015-12-29 Ortho-Clinical Diagnostics, Inc. Peptides for the detection of hiv-1 group o
FR2874017B1 (fr) * 2004-08-06 2006-11-24 Bio Rad Pasteur Sa Peptides vih-1 modifies et leur utilisation en detection d'anticorps anti-vih
EP2864787B1 (en) * 2012-06-22 2017-11-01 Bio-Rad Laboratories, Inc. Human factor xiii as a normalization control for immunoassays
CN112481246B (zh) * 2020-12-16 2022-03-29 熊猫乳品集团股份有限公司 一种生物活性多肽fspankkltpkky及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204259A (en) 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
CA2107732C (en) 1992-10-06 2003-04-08 Lutz G. Gurtler Retrovirus from the hiv group and its use
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
GB9410044D0 (en) 1994-05-19 1994-07-06 Int Murex Tech Corp Assay
DE4430998A1 (de) 1994-07-25 1996-02-01 Boehringer Mannheim Gmbh Metallchelat-markierte Peptide
ES2293643T5 (es) * 1994-10-20 2012-02-02 Institut Pasteur Secuencias nucleotídicas de antígenos retrovíricos vih-1 del grupo (o subgrupo) o.
DE19505262C2 (de) 1995-02-16 1998-06-18 Behring Diagnostics Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
FR2731013B1 (fr) * 1995-02-27 1997-05-16 Inst Nat Sante Rech Med Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
WO1996027012A1 (en) 1995-03-02 1996-09-06 Akzo Nobel N.V. Specific hiv-1 group o antigens
US5569553A (en) 1995-03-08 1996-10-29 Wilson Greatbatch Ltd. Battery design for achieving end-of-life indication during electrical discharge
DE19622088A1 (de) 1996-05-31 1997-12-04 Boehringer Mannheim Gmbh Anti-HIV-Antikörper als Kontrollproben
ATE343590T1 (de) * 1997-04-09 2006-11-15 Bio Rad Pasteur Synthetische peptide für testverfahren zur bestimmung der infektion mit virus hiv1 der gruppe o
US6511801B1 (en) 1997-07-18 2003-01-28 Innogenetics, N.V. HIV-1 group O antigens and uses thereof

Also Published As

Publication number Publication date
PL336115A1 (en) 2000-06-05
BR9809078A (pt) 2000-08-01
IL132166A (en) 2006-12-10
ES2275305T3 (es) 2007-06-01
KR100451312B1 (ko) 2004-10-06
US20060234213A1 (en) 2006-10-19
CZ300927B6 (cs) 2009-09-16
CA2286344A1 (fr) 1998-10-15
CA2286344C (fr) 2012-08-07
PL194863B1 (pl) 2007-07-31
IL132166A0 (en) 2001-03-19
CN1256695A (zh) 2000-06-14
BRPI9809078B8 (pt) 2021-05-25
AU7338698A (en) 1998-10-30
PT973802E (pt) 2007-01-31
BR9809078B1 (pt) 2012-12-11
KR20010006216A (ko) 2001-01-26
EP0973802A1 (fr) 2000-01-26
CN1215082C (zh) 2005-08-17
JP2001519800A (ja) 2001-10-23
DE69836265T2 (de) 2007-05-31
DE69836265D1 (de) 2006-12-07
JP3560987B2 (ja) 2004-09-02
RU2184742C2 (ru) 2002-07-10
CZ357599A3 (cs) 2000-06-14
TR199902757T2 (xx) 2000-02-21
NO994929L (no) 1999-12-08
AU740231B2 (en) 2001-11-01
NO329149B1 (no) 2010-08-30
NZ500015A (en) 2001-06-29
WO1998045323A1 (fr) 1998-10-15
EP0973802B1 (fr) 2006-10-25
ATE343590T1 (de) 2006-11-15
US7838001B2 (en) 2010-11-23
US7053175B1 (en) 2006-05-30

Similar Documents

Publication Publication Date Title
Savage et al. Epidermal growth factor: location of disulfide bonds
DeLange et al. Calf and pea histone IV: II. The complete amino acid sequence of calf thymus histone IV; presence of ε-N-acetyllysine
Karplus et al. Amino acid sequence of spinach ferredoxin: NADP oxidoreductase
Denkewalter et al. Total synthesis of an enzyme. I. Objective and strategy
Tugyi et al. The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein D derived epitope peptide
CA1246054A (en) Synthetic st toxin, process for its preparation and its use as a vaccinating agent
ATE102949T1 (de) Verfahren zur herstellung von retro-inversopeptiden und dessen zwischenprodukte.
ATE449965T1 (de) Diagnostisches und therapeutisches epitop
MX2023005770A (es) Tetrapeptido y composiciones que comprenden tetrapeptidos.
MX2023005771A (es) Tetrapeptido y composiciones que comprenden tetrapeptidos.
NO994929D0 (no) Syntetiske peptider, nyttige i biologiske tester, for paavisning av infeksjoner foraarsaket av gruppe 0 HIV-1 virus
Wakamiya et al. Lanthiopeptin, a new peptide effective against herpes simplex virus: structural determination and comparison with Ro 09-0198, an immunopotentiating peptide
JP2009544638A (ja) タンパク質結合メトトレキサート誘導体、及びそれを含有する薬剤
DE60219645D1 (de) Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
ES487926A0 (es) Procedimiento de fabricacion de compuestos que resultan de la fijacion de muramilpeptidos, sus homologos y derivados
ATE290088T1 (de) Verfahren zur spaltung eines chimeren proteins mittels eines 'processing'-enzyms
Bruton The infrastructure of valyl-transfer Ribonucleic Acid synthetase from yeast
MERRILL et al. Amino acid sequence of UP1, an hnRNP‐derived single‐stranded nucleic acid binding protein from calf thymus
Habuchi et al. Sea urchin egg receptor for sperm: the oligosaccharide chains stabilize sperm binding
AU623687B2 (en) New pentapeptide and a process for the preparation thereof
Gish Studies on the Amino Acid Sequence of Tobacco Mosaic Virus (TMV) Protein. IV. The Amino Acid Sequences of an Eicosapeptide and a Heptadecapeptide Isolated from a Tryptic Digest of TMV Protein1
Morley et al. MPF analogue with high stability to proteolysis
ATE85077T1 (de) Enzym zur alpha-amidierung von c-termini und verfahren zu dessen herstellung.
Doolittle Sequencing peptides and proteins lacking free α-amino groups
Gittel et al. Directed N-terminal elongation of unprotected peptides catalyzed by cathepsin C in water

Legal Events

Date Code Title Description
MK1K Patent expired